TOP TIERMARKET NEWSWIRE
News & sentiment

NEWAMSTERDAM PHARMA (NAMS) — News & AI sentiment

NEWAMSTERDAM PHARMA (NAMS) news roundup. 3 stories in the past week, 8 over 30 days. Average 30-day sentiment is 54.4/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 4 sales totalling $7.8M — net selling of $7.8M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
3
avg sentiment 55.7/100
30d stories
8
avg sentiment 54.4/100
Insider net (90d)
$7.8M
0 buys · 4 sells
Congress (90d)
0
0 buys · 0 sells

NAMS news in the last 24 hours, 7 days, 30 days and 90 days

How much NAMS coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowNAMS storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days355.7/100NAMS headlines →
Last 30 days854.4/100NAMS headlines →
Last 90 days2553.6/100NAMS headlines →

Latest stories on NAMS

5d ago
5d ago
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure
Investing.com Analyst Ratings56 · neutralanalyst
5d ago
Sep 3
Sep 2
Sep 2
Aug 26
Aug 14
Aug 9
Aug 6
Aug 5
Aug 5
Aug 5
Aug 5
Jul 29
Jul 29
Jul 26
Jul 24
Jul 24
Jul 22
Jul 22
Jefferies reiterates NewAmsterdam Pharma stock rating ahead of data
Investing.com Analyst Ratings56 · neutralanalyst
Jul 20
Why is NewAmsterdam Pharma stock sliding today?
Investing.com Markets42 · neutralgeneral
Jul 20
Jul 2
Jul 1
Open NAMS in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →